STAQ Pharma

STAQ Pharma is proud to be one of the country’s first 503Bs designed and built from the floor up to comply specifically with FDA regulations as a cGMP facility. Late in 2013, in response to then poor oversight by the state boards of pharmacy, the Federal Drug Administration (FDA) implemented the Drug Quality and Security Act (DQSA) and broke pharmaceuticals into two sectors: 503A and 503B. Pharmaceutical outsourcing facilities like STAQ, which compound, manufacture, and sell medications in large batches to healthcare facilities were required to be, or become, 503B. For most pharmaceuticals, this meant converting their existing 503A facilities to conform to the new regulations and standards. STAQ’s goal from day one has been to help ensure the highest possible quality of surgical medications for children and adults. With more than 4,500 square feet of highly automated ISO 7 and ISO 8 cleanroom space and an extensive Quality Management System operation, STAQ’s outsourcing facility is designed to meet the highest of industry standards. We conduct independent testing analysis to ensure stability, sterility, potency and lack of endotoxins on every batch of medication we compound. And, each syringe we fill is individually inspected and verified before it can pass from our doors to yours. Plus, we have integrated robotics to minimize human touch and maximize accuracy and efficiency. Simply put, STAQ provides top quality pharmaceutical compounding with state-of-the-art manufacturing.